Full-Time

Staff Product Manager

Hyperfine

Hyperfine

51-200 employees

Portable bedside MRI system for hospitals

Compensation Overview

$194k - $223k/yr

+ Bonus + Equity

No H1B Sponsorship

Palo Alto, CA, USA

Hybrid

Minimum 3 days on-site per week in Palo Alto.

Category
Product (1)
Required Skills
Market Research
Product Management
Requirements
  • BS, MS, or PhD in engineering or relevant field
  • 7+ years Software Product Management experience with a history of defining and launching software and hardware solutions that unlocked new use cases for medical devices.
  • Ability to make informed decisions that drive product success and business growth based on user and market research.
  • Experience developing business plans.
  • Ability to translate and articulate complicated business problems into easily understood solutions and functional requirements.
  • Ability to define and analyze metrics that inform the success of products.
  • Experience working on products across the full product lifecycle (conception, development, go-to-market, and post launch support).
  • Proven written and oral communication skills and ability to influence colleagues.
Responsibilities
  • Lead the technical launch of software releases, including image quality improvements, new user capabilities, and expansion of imaging offerings, ensuring readiness across product, engineering, and commercial teams.
  • Conduct user discovery through interviews, workflow analysis, and market research to identify unmet needs, new opportunities, and potential partnerships.
  • Analyze the competitive landscape, reimbursement environment, and industry trends to inform product direction and strategic decisions.
  • Develop and maintain product requirements, user needs, and acceptance criteria, ensuring alignment with business objectives, clinical needs, and regulatory requirements.
  • Prioritize product features across hardware and software by synthesizing input from customers, marketing, commercial teams, and overall business priorities.
  • Drive prioritization and trade-off decisions, ensuring delivery of high-impact features that meet customer needs and product specifications.
  • Build and communicate business cases to support investment decisions and new product or feature development.
  • Engage and align cross-functional stakeholders—including engineering, clinical, regulatory, marketing, and external partners—to shape, validate, and execute the product's roadmap.
  • Deliver product training to internal teams, particularly commercial and field organizations, to ensure successful product adoption and customer engagement.
  • Serve as the internal voice of the customer, advocating across imaging, hardware, and software while balancing user needs with business objectives.
  • Act as a product evangelist, representing the company at trade shows and in high-stakes, high-impact business settings.

Hyperfine creates medical imaging tools for hospitals, focusing on the Swoop system, the first FDA-cleared portable ultra-low field MRI that can image a patient’s brain at the bedside. How it works: a compact, portable MRI device is brought to the patient in settings like intensive care units, performing brain scans without moving the patient to a radiology suite. The open, safe design allows family members to stay nearby during imaging. Differentiation: it is already FDA-cleared and designed for point-of-care use, enabling bedside decision-making, faster treatment decisions, quicker discharges, and more efficient use of hospital staff and resources at a lower cost compared to traditional MRI workflows. Revenue model: Hyperfine sells the Swoop system and related services to hospitals, clinics, and other healthcare facilities. Goal: improve patient care by bringing diagnostic imaging directly to patients, increasing access to timely brain imaging and streamlining clinical workflows.

Company Size

51-200

Company Stage

IPO

Headquarters

Guilford, Connecticut

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue surged 83% to $3.9M from next-gen Swoop sales.
  • NVIDIA March 2026 collaboration accelerates AI image reconstruction and scan times.
  • $3.7M Gates Foundation grant funds neonatal imaging in low-resource settings.

What critics are saying

  • GE Healthcare and Siemens launch competing ultra-low field MRIs within 12-24 months.
  • $40.8M cash lasts to late 2027 without profitability or new funding.
  • Horizon $40M loan's 10.75% interest and warrants dilute equity immediately.

What makes Hyperfine unique

  • Swoop system delivers first FDA-cleared portable ultra-low field MRI for bedside brain imaging.
  • Optive AI software upgrade cleared December 2025 enhances stroke detection via multi-direction DWI.
  • Open design allows family presence during ICU scans, unlike traditional high-field MRIs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Hyperfine who can refer or advise you

Benefits

Remote Work Options

Hybrid Work Options

Wellness Program

Mental Health Support

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

0%
The Associated Press
Apr 9th, 2026
Hyperfine wins CE and UKCA marks for next-gen Swoop MRI system and Optive AI software

Hyperfine has received CE marking and UK Conformity Assessment approval for its next-generation Swoop portable MRI system and latest Optive AI software, enabling commercialisation across Europe and the UK. The approvals mark a key milestone in the company's international growth strategy. The next-generation Swoop system, FDA-cleared in Q2 2025, delivers improved image quality and workflow for brain imaging. The updated Optive AI software includes multi-direction diffusion-weighted imaging capabilities, enhancing stroke detection similar to high-field MRI scanners. The technology is currently distributed across over a dozen European countries through Hyperfine's network. The company plans to begin commercialisation of the new system and software in Europe and the UK in early Q3 2026, ahead of internal expectations.

Yahoo Finance
Mar 19th, 2026
Hyperfine reports $5.3M Q4 revenue, up 128%, targets $21M in 2026 with 50%+ margins

Hyperfine Inc reported record fourth-quarter revenue of $5.3 million, up 128% year-over-year, driven by strong performance of its next-generation Swoop scanner. The medical imaging company sold 16 units in Q4, compared to nine units in the prior-year period. Gross margin expanded to 50.9%, up 1,530 basis points from Q4 2024, whilst net loss narrowed to $5.9 million from $10.4 million. Full-year 2025 revenue reached $13.6 million, up 5% from 2024. The company received FDA clearance for updated Optive AI software and gained approval for its first-generation Swoop system in India. Hyperfine reduced cash burn by 30% year-over-year to $5.7 million. For 2026, the company projects revenue of $20 million to $22 million, representing 55% growth at the midpoint, with gross margins of 50% to 55%.

Yahoo Finance
Mar 18th, 2026
Hyperfine reports $5M Q4 revenue as portable brain MRI gains traction in hospitals

Hyperfine reported fourth-quarter revenue exceeding $5 million, driven by accelerating adoption of its second-generation Swoop portable brain MRI system and Optive AI software. CEO Maria Sainz described the combination as a "market turning point" for portable brain MRI, highlighting diagnostic-quality imaging from ultra-low field magnets. The company has sold over a dozen next-generation systems since June 2025, focusing on critical care, emergency departments and neurology offices. The FDA cleared a software update in December 2025 featuring diffusion-weighted imaging for stroke workflows. Hyperfine cited external validation including published health economic data from Jefferson Abington Hospital showing cost savings across 143 scans. Yale School of Medicine's PRIME study evaluating AI-powered portable MRI in emergency departments completed enrollment ahead of schedule, with results expected later in 2026.

Stock Titan
Mar 18th, 2026
Hyperfine (NASDAQ: HYPR) adds $40M loan facility and over 1.0M stock warrants

Hyperfine arranged a $40M senior secured loan with Horizon, drawing $15M initially, at a minimum 10.75% rate and issuing over 1.0M stock warrants at $1.20 per share.

Business Wire
Nov 20th, 2025
Hyperfine Awarded $3.7 Million Grant to Advance Global Brain Health

$3.7M grant supports expanded use of portable MRI to evaluate brain development and guide targeted health interventions in underserved communities.